Arbutus announces resignation of board member

Warminster, pa., jan. 27, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that tram tran, md has notified the company of her intention to resign from the company's board of directors, effective february 26, 2023. dr. tran will be transitioning into public service commencing february 27, 2023, that will preclude her participation on the arbutus and other pharmaceutical and biotechnology boards.
ABUS Ratings Summary
ABUS Quant Ranking